Encodia, Inc. is a biotechnology company based in San Diego, California, founded in 2015. The company specializes in proteomics research, providing innovative solutions for protein analysis through its proprietary technology. Encodia's platform utilizes a novel reverse-translation process that converts peptide sequence information into a DNA library, facilitating scalable and efficient protein sequencing. This technology allows researchers to gain comprehensive insights into cellular processes, thereby advancing personalized medicine and accelerating the discovery of novel approaches to address complex diseases. By democratizing protein sequencing, Encodia aims to enhance the capabilities of scientists in their pursuit of understanding the proteome.
Compass Therapeutics
Private Equity Round in 2020
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.
Verve Therapeutics
Series A in 2020
Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.
Omniome, Inc. is a biotechnology company based in San Diego, California, that specializes in developing a proprietary DNA sequencing platform aimed at providing high accuracy in clinical sequencing. Founded in 2013, Omniome utilizes its Sequencing By Binding technology to enhance nucleotide and DNA matching, leveraging the natural matching capabilities of polymerases. This innovative approach allows researchers to achieve accurate and rapid sequencing results while maintaining low costs. The company's ambition is to become a leading name in DNA sequencing, particularly in advancing cancer diagnostics and improving outcomes in clinical settings.
Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.
AiCure, LLC is a New York-based company that specializes in developing scalable medication adherence solutions and intelligent medical assistant technologies. Utilizing a visual recognition platform, AiCure's software monitors patient progress through mobile devices, confirming medication ingestion in clinical trials and among high-risk populations. The platform employs patented facial recognition and motion-sensing technology to identify patients and medications, detect diversion, and capture evidence of adherence in real-time. This data enables immediate intervention and longitudinal tracking of adherence patterns, ultimately enhancing treatment outcomes and reducing healthcare costs. AiCure's capabilities also facilitate remote patient engagement in clinical trials by measuring digital biomarkers and monitoring patient dosing. Founded in 2010, AiCure aims to transform healthcare delivery systems through advanced data analytics and artificial intelligence.
Blackthorn Therapeutics
Series B in 2019
Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.
Thrive Earlier Detection
Series A in 2019
Thrive Earlier Detection Corp. is a healthcare company focused on revolutionizing cancer diagnosis through its innovative blood testing platform. The company specializes in CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to detect various types of cancer at their earliest stages, even before symptoms arise. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate earlier cancer detection into routine medical care. The company's approach combines targeted DNA and protein analysis with real-world data and machine learning to provide comprehensive result interpretation and facilitate follow-up testing and oncology care. Thrive Earlier Detection Corp. operates as a subsidiary of Exact Sciences Corporation, reflecting its commitment to enhancing cancer detection and improving patient outcomes.
Verve Therapeutics
Series A in 2019
Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.
Omniome, Inc. is a biotechnology company based in San Diego, California, that specializes in developing a proprietary DNA sequencing platform aimed at providing high accuracy in clinical sequencing. Founded in 2013, Omniome utilizes its Sequencing By Binding technology to enhance nucleotide and DNA matching, leveraging the natural matching capabilities of polymerases. This innovative approach allows researchers to achieve accurate and rapid sequencing results while maintaining low costs. The company's ambition is to become a leading name in DNA sequencing, particularly in advancing cancer diagnostics and improving outcomes in clinical settings.
Verana Health
Series C in 2018
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.
Qihan Biotech
Series A in 2018
Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.
Compass Therapeutics
Series A in 2018
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.
Cytrellis Biosystems
Series B in 2018
Cytrellis Biosystems, Inc. is a clinical stage medical technology company focused on designing and developing innovative devices for dermatology, scar reduction, and aesthetic medicine. Founded in 2011 and headquartered in Sherborn, Massachusetts, the company aims to address age-related skin changes through non-surgical solutions. Its products are specifically engineered to remove sagging skin without the need for invasive procedures or scarring, thereby offering aesthetic practitioners enhanced capabilities to improve the appearance of aging skin. Cytrellis Biosystems is dedicated to advancing the field of aesthetic medicine with its cutting-edge technologies.
Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.
AiCure, LLC is a New York-based company that specializes in developing scalable medication adherence solutions and intelligent medical assistant technologies. Utilizing a visual recognition platform, AiCure's software monitors patient progress through mobile devices, confirming medication ingestion in clinical trials and among high-risk populations. The platform employs patented facial recognition and motion-sensing technology to identify patients and medications, detect diversion, and capture evidence of adherence in real-time. This data enables immediate intervention and longitudinal tracking of adherence patterns, ultimately enhancing treatment outcomes and reducing healthcare costs. AiCure's capabilities also facilitate remote patient engagement in clinical trials by measuring digital biomarkers and monitoring patient dosing. Founded in 2010, AiCure aims to transform healthcare delivery systems through advanced data analytics and artificial intelligence.
Twist Bioscience
Venture Round in 2017
Twist Bioscience Corporation is a synthetic biology company that specializes in the manufacture and sale of synthetic DNA-based products. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes a proprietary semiconductor-based DNA synthesis platform that writes DNA on silicon chips, allowing for the rapid and cost-effective production of high-quality synthetic DNA. Twist Bioscience's offerings include synthetic genes, tools for sample preparation, antibody libraries for drug discovery, and DNA as a medium for digital data storage. The company serves various sectors, including healthcare, agriculture, and industrial chemicals, supporting customers in their efforts to enhance lives and promote sustainability. Through its innovative platform, Twist Bioscience aims to overcome traditional inefficiencies in DNA synthesis, enabling researchers to accelerate their projects.
Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.
Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.
Blackthorn Therapeutics
Series A in 2017
Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.
BlueTalon
Series A in 2016
BlueTalon, Inc. is a data collaboration and unification technology company based in Redwood City, California, founded in 2013. The company specializes in data-centric security solutions designed to protect sensitive data while enabling seamless access across various platforms, including Hadoop, Spark, and SQL-based environments. BlueTalon's offerings include the Control Your Data platform, which provides comprehensive data control, and the BlueTalon Policy Engine, which implements precise and consistent user access controls. This technology facilitates collaboration on big data projects while ensuring compliance with regulatory requirements through detailed auditing capabilities. BlueTalon's solutions allow organizations to maintain visibility and control over their data ecosystems, effectively bridging departmental and geographic boundaries without requiring customization of existing databases or applications. The company has been recognized as a leader in security and big data initiatives, with deployments among Fortune 100 companies to enhance data security and eliminate vulnerabilities. In 2019, BlueTalon became a subsidiary of Microsoft Corporation.
GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.
AiCure, LLC is a New York-based company that specializes in developing scalable medication adherence solutions and intelligent medical assistant technologies. Utilizing a visual recognition platform, AiCure's software monitors patient progress through mobile devices, confirming medication ingestion in clinical trials and among high-risk populations. The platform employs patented facial recognition and motion-sensing technology to identify patients and medications, detect diversion, and capture evidence of adherence in real-time. This data enables immediate intervention and longitudinal tracking of adherence patterns, ultimately enhancing treatment outcomes and reducing healthcare costs. AiCure's capabilities also facilitate remote patient engagement in clinical trials by measuring digital biomarkers and monitoring patient dosing. Founded in 2010, AiCure aims to transform healthcare delivery systems through advanced data analytics and artificial intelligence.
Denali Therapeutics
Series A in 2015
Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.
Verana Health
Series B in 2015
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.